PATENT CLAIM ANALYSIS

Application Number: 16265109
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-05
Patent Classification: ["514", "428000"]

Abstract:
The disclosure provides methods for treating estrogen receptor positive (ER + ) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER +  cancers.

Claim (Index 10):
The method of  claim 8 , wherein the additional agent is a CDK4/6 inhibitor.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 99.0
- Lexical Diversity: 1.28
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15939218', '16475980', '14645578', '14753397', '15129197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7468789343035139
- 35 USC 102 Novelty (BERT): 0.5813562525967726
- Combined Prediction Score: 0.7303266661328398
- Mean Citation Score: 323.4696600000001
- Max Citation Score: 491.87918
- Similarity Product: 364.02583846804856

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test